Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Express Scripts
McKesson
Colorcon
Harvard Business School

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR INSULIN ASPART; INSULIN DEGLUDEC


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Insulin Aspart; Insulin Degludec

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00612040 ↗ Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes Completed Novo Nordisk A/S Phase 2 2008-01-01 This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with insulin aspart in subjects with type 1 diabetes.
NCT00613951 ↗ Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 2 2008-01-01 This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (Soluble Insulin Analogue Combination [SIAC], insulin degludec/insulin aspart) formulations with each other and with biphasic insulin aspart 30, all in combination with metformin in insulin naive subjects with type 2 diabetes.
NCT00614055 ↗ Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 2 2008-01-01 This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes.
NCT00842361 ↗ Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus Completed Novo Nordisk A/S Phase 2 2009-01-01 This trial is conducted in Japan. The aim of this clinical trial is to investigate the safety (with emphasis on hypoglycaemia) after switching from long-acting insulin analogue/intermediate-acting insulin or pre-mixed insulin/pre-mixed insulin analogue on a twice daily regimen to NN5401 (SIAC, insulin degludec/insulin aspart) on a twice daily regimen in subjects with type 2 diabetes mellitus.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Insulin Aspart; Insulin Degludec

Condition Name

Condition Name for Insulin Aspart; Insulin Degludec
Intervention Trials
Diabetes 47
Diabetes Mellitus, Type 1 23
Diabetes Mellitus, Type 2 23
Healthy 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Insulin Aspart; Insulin Degludec
Intervention Trials
Diabetes Mellitus 49
Diabetes Mellitus, Type 2 27
Diabetes Mellitus, Type 1 27
Gastroparesis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Insulin Aspart; Insulin Degludec

Trials by Country

Trials by Country for Insulin Aspart; Insulin Degludec
Location Trials
United States 365
India 58
China 39
Canada 33
Germany 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Insulin Aspart; Insulin Degludec
Location Trials
California 21
Florida 19
Texas 19
New York 16
North Carolina 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Insulin Aspart; Insulin Degludec

Clinical Trial Phase

Clinical Trial Phase for Insulin Aspart; Insulin Degludec
Clinical Trial Phase Trials
Phase 4 4
Phase 3 28
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Insulin Aspart; Insulin Degludec
Clinical Trial Phase Trials
Completed 52
Recruiting 4
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Insulin Aspart; Insulin Degludec

Sponsor Name

Sponsor Name for Insulin Aspart; Insulin Degludec
Sponsor Trials
Novo Nordisk A/S 52
HNEC TEST 1
University Hospital Inselspital, Berne 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Insulin Aspart; Insulin Degludec
Sponsor Trials
Industry 52
Other 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Medtronic
Baxter
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.